Table 1 Optimization of SMARCA2/A4 monovalent degraders

From: Rational design of potent small-molecule SMARCA2/A4 degraders acting via the recruitment of FBXO22

Compound

SMARCA2 DC50 (nM)

SMARCA2 Dmax (%)

SMARCA4 DC50 (nM)

SMARCA4 Dmax (%)

1

>10,000

--

>10,000

--

2

13 ± 40

38 ± 7.1

8.3 ± 2.4

50 ± 2.2

3

18 ± 25

38 ± 12

8.3 ± 5.3

43 ± 7.1

4

16 ± 6.5

51 ± 18

15 ± 9.9

25 ± 5.9

5

5.9 ± 2.1

82 ± 10

1.2 ± 0.75

99 ± 2.0

G-6599 (6)

0.017 ± 0.0084

96 ± 2.0

0.057 ± 0.071

94 ± 3.1

  1. Degradation data of SMARCA2/A4 compounds determined by a high-throughput immunofluorescence assay monitoring SMARCA2 or SMARCA4 in SW1573 cells at 20 h time point. Data are reported as an average of a minimum of three independent experiments with error reported as standard deviation. Relative DC50 values were fitted from a dose response curve. The maximum % degradation (Dmax) was additionally determined from dose-response curves. See Fig. 1b and Supplementary Fig. 1c for associated structures.